Field notes on the future of regulatory reasoning.
Practical writing from our team on how MedTech companies are moving from spreadsheets and retainers to intelligence that lives inside the workflow.
A Scientific Framework for Assessing the Regulatory Impact of Medical Device Changes
Why ad-hoc change reviews fail under inspection, and what a defensible, scientific framework actually looks like. With Change Clarifier mapping.Every ...
Risk Evidence Based Change Management for Medical Devices
Manual change reviews miss the mark. FY 2024 FDA data shows the cost. Here is what a risk evidence based approach looks like, and how it works.Every m...
The Role of a Quality Management System Before and After Market
How a properly engineered QMS protects a MedTech company from concept through commercialization, and what FY 2024 FDA inspection data shows about wher...
The MedTech Founder's Commercialization Roadmap
By regulifyAI May 11, 2026 12 min readThe journey from medical device concept to commercial clearance takes 3 to 7 years and consumes mi...
Clinical Literature Evaluation: How RegulifyAI Is Transforming Months of Process Into Weeks
The systematic review of clinical literature is one of the most time-intensive bottlenecks in medical device regulation. Here's how AI-powered automat...
Your DHF Is Not Inspection-Ready Until You Have Tested It Like an Investigator
I want to share something that took me years to learn the hard way. The difference between a DHF that survives an FDA inspection and one that generate...
Stop Just Storing Your DHF. Start Making It Audit-Ready — Always!
Your Design History File (DHF) isn’t just documentation. It’s your single source of product truth—and your first line of defense in an audit.Yet most ...
Design History File (DHF) Management with Traceability and Change Control
I still remember the first time an FDA investigator pulled a design change record from a DHF binder and asked the quality manager sitting next to me, ...
A Universal Framework for Assessing the Impact of Medical Device Changes
Last month, I sat across from a quality director at a Class II cardiovascular device manufacturer in Boston. Her team had just received the third FDA ...
The Role of Cybersecurity in Overall Risk Assessment for MedTech Devices: A Complete Integration Guide
Recently, I met with a former colleague to discuss the progress the Regulify.AI team is making. We previously worked together at the same MedTech comp...
Risk Manager: Comprehensive Risk Assessment Aligned with ISO 14971
A few years ago, I sat across from a quality manager at a mid-sized MedTech company in Boston. Her desk was buried under color-coded Excel files—risk ...
Clinical Literature Evaluation: Turning Evidence into Regulatory Confidence
A few months ago, I spent an afternoon with a regulatory affairs director at a Class III device company in San Diego. Her team was preparing a clinica...
De-Risking Commercialization for Early MedTech/BioTech Innovations
While demoing Regulify.AI to potential MedTech customers, we learned how early-stage innovators often struggle to navigate the end-to-end commercializ...